Nivolumab +/− Ipilimumab Before Surgery for Bladder Cancer

Not currently recruiting at 8 trial locations

Overseen By Scott Niglio, MD

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Memorial Sloan Kettering Cancer Center

Must not be taking: Corticosteroids, Immunosuppressives, Checkpoint inhibitors, others

Disqualifiers: Autoimmune disease, Heart failure, Stroke, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Breakthrough Therapy This drug has been fast-tracked for approval by the FDA given its high promise

Compensation: Varies

Number of Visits: 5

Duration: 10 weeks

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores whether using the immunotherapy drugs nivolumab and ipilimumab before bladder cancer surgery can safely shrink tumors, potentially enhancing the surgery's effectiveness. Researchers are testing various combinations and schedules of these drugs to determine the best approach. The trial seeks participants with muscle-invasive bladder cancer or certain upper urinary tract cancers who cannot undergo standard chemotherapy. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, if you are on systemic corticosteroids or other immunosuppressive medications, you must stop them at least 14 days before starting the study treatment.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that nivolumab and ipilimumab have been studied for bladder cancer and other conditions. Nivolumab often causes side effects like tiredness, muscle pain, nausea, and loss of appetite when used for bladder cancer. Although rare, serious reactions can include lung problems and infections.

Studies indicate that nivolumab and ipilimumab can work well together. This combination has been tested in patients with advanced bladder cancer and has shown promise in shrinking tumors. However, it can also lead to serious side effects, such as inflammation in the lungs or other organs, and infections.

Both drugs are already approved for treating other types of cancer, indicating they have been thoroughly studied. However, like any treatment, they come with risks. Patients should consider these potential side effects and discuss them with their doctors before joining a trial. ^{1 2 3 4 5}

Why are researchers excited about this trial's treatments?

Unlike the standard of care for bladder cancer, which typically involves chemotherapy or surgery, the combination of Nivolumab and Ipilimumab offers a novel approach by harnessing the power of the immune system. Nivolumab is a PD-1 inhibitor, while Ipilimumab targets CTLA-4, both of which help to unleash the immune system against cancer cells. Researchers are excited about these treatments because they have the potential to work synergistically, offering a more effective response against the tumor. Additionally, this immunotherapy combination can be administered before surgery, potentially shrinking the tumor size and making surgical removal easier. This method could lead to better outcomes for patients who are ineligible for standard chemotherapy options.

What evidence suggests that this trial's treatments could be effective for bladder cancer?

Research has shown that using the drug nivolumab alone yields promising results for treating bladder cancer. For patients with muscle-invasive urothelial carcinoma, nivolumab reduced the chance of cancer returning after surgery by 30%. In this trial, some participants will receive nivolumab alone, while others will receive a combination of nivolumab and ipilimumab. When combined, these drugs have caused cancer to shrink in 38.5% of patients with advanced bladder cancer. In some studies, 21% of patients experienced partial or complete disappearance of their cancer, which extended their lives. These findings suggest that these treatments could potentially shrink bladder tumors and improve surgery outcomes. ^{6 7 8 9 10}

Who Is on the Research Team?

Scott Niglio, MD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Are You a Good Fit for This Trial?

This trial is for adults with bladder cancer who can't have chemotherapy. They must have a certain type of bladder cancer that hasn't spread beyond the pelvis and be fit for surgery. People with prior systemic cancer treatments, active autoimmune diseases needing steroids, recent heart attacks or strokes, HIV/AIDS, or those unwilling to use contraception are excluded.

Inclusion Criteria

My bladder cancer diagnosis is mainly urothelial.

Before joining the study, your blood tests need to show specific levels of white blood cells, platelets, bilirubin, and liver enzymes. If you are taking blood-thinning medication, your dose should be consistent.

I have a confirmed high-grade cancer in my upper urinary tract.

Exclusion Criteria

I've had chemotherapy for bladder cancer, including treatments to boost my immune system.

I am a male willing to use contraception during and for 31 weeks after treatment.

You are being held against your will for treatment of a mental or physical illness.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive immunotherapy with nivolumab alone or in combination with ipilimumab prior to surgery

10 weeks

5 visits (in-person) for Cohort 1, 3 visits (in-person) for Cohort 3, 4 visits (in-person) for Cohort 2

Surgery

Planned bladder cancer surgery to assess the effect of the immunotherapy

Follow-up

Participants are monitored for safety and effectiveness after treatment and surgery

4-8 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Ipilimumab
• Nivolumab
• Radical cystectomy

Trial Overview

The study tests if immunotherapy drugs Nivolumab alone or combined with Ipilimumab are safe before surgery without delaying it. The goal is to see if these drugs shrink the tumor to aid surgical success in bladder cancer patients.

How Is the Trial Designed?

Group I: Cohort U (UTUC patients) is independent from Cohorts 1 - 3. ( who are cisplatin-ineligible) Experimental Treatment 3 Interventions

Ipilimumab 3 mg/kg and Nivolumab 1 mg/kg on day 1, of each cycle, followed by Nivolumab 3 mg/kg on day 22 and Ipilimumab 3mg/kg and Nivolumab 1mg/kg on day 45.

Group II: Cohort 3 Experimental Treatment 3 Interventions

Ipilimumab 3 mg/kg on day 1 each cycle and Nivolumab 1 mg/kg on day 1 of each cycle for a total of 3 cycles. Each cycle will be three weeks long and treatment will occur during weeks 0, 3, and 6.

Group III: Cohort 2 Experimental Treatment 3 Interventions

Ipilimumab 3 mg/kg and Nivolumab 1 mg/kg on day 1 of each cycle, followed by Nivolumab 3 mg/kg on day 22 of each cycle for a total of 2 cycles. Each cycle will be six weeks long. Ipilimumab and Nivolumab will occur on weeks 0 and 6 while Nivolumab alone will occur on weeks 3 and 9.

Group IV: Cohort 1 Experimental Treatment 2 Interventions

Nivolumab 3 mg/kg on day 1 of each cycle for a total of 5 cycles. Each cycle will be two weeks long and treatment will occur during weeks 0, 2, 4, 6, and 8.

Ipilimumab is already approved in United States, European Union for the following indications:

Approved in United States as Yervoy for:

• Advanced melanoma
• Stage III unresectable melanoma
• Stage IV metastatic melanoma

Approved in European Union as Yervoy for:

• Advanced melanoma
• Stage III unresectable melanoma
• Stage IV metastatic melanoma

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials

1,998

Recruited

602,000+

Published Research Related to This Trial

In a study of 95 patients with muscle-invasive bladder cancer receiving two cycles of neoadjuvant atezolizumab before surgery, 44% experienced treatment-related adverse events, but no surgeries were delayed due to these toxicities.

The use of neoadjuvant atezolizumab was found to be well tolerated, with surgical complication rates not significantly impacted, indicating its safety in the pre-surgical setting.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial. Szabados, B., Rodriguez-Vida, A., Durán, I., et al.[2022]

Nivolumab, an anti-PD-1 antibody, was administered to a 63-year-old female patient with metastatic melanoma after renal transplantation, highlighting the potential for anti-tumor activity in high-risk patients, despite the challenges of concurrent immunosuppression.

The patient experienced acute renal allograft rejection and renal failure shortly after starting nivolumab, indicating significant risks associated with this treatment in transplant recipients, but she later showed a positive clinical response after re-challenging with nivolumab while on hemodialysis.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Antitumor activity of nivolumab on hemodialysis after renal allograft rejection. Ong, M., Ibrahim, AM., Bourassa-Blanchette, S., et al.[2023]

In a study of 44 patients with resectable stage IB to IIIA non-small cell lung cancer, both neoadjuvant chemotherapy combined with nivolumab and with ipilimumab showed high surgical resection rates, with 100% of patients in the nivolumab group and 90.9% in the ipilimumab group undergoing successful surgeries.

Despite the complexity of the procedures, with about half of the cases rated as challenging, the safety profile was acceptable, with 18.2% of nivolumab patients and 20% of ipilimumab patients experiencing significant complications (grade 3 or greater).

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer. Feldman, H., Sepesi, B., Leung, CH., et al.[2023]

Nivolumab (Opdivo) significantly improves overall survival and response rates in previously-treated patients with advanced nonsquamous non-small cell lung cancer (NSCLC) compared to docetaxel, as shown in the CheckMate 057 trial.

Nivolumab has a manageable adverse event profile and is better tolerated than docetaxel, making it a valuable treatment option for patients who have progressed after chemotherapy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer. Keating, GM.[2018]

Neoadjuvant immunotherapy using immune checkpoint inhibitors (ICIs) like anti-PD-(L)1 and anti-CTLA-4 antibodies shows promising efficacy in localized muscle-invasive bladder cancer, with pathological complete response rates between 31% and 46%.

The safety profile of these treatments is generally acceptable, with severe adverse events reported in 6% to 41% of patients, indicating that while there are risks, the potential benefits warrant further investigation.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Neoadjuvant Immunotherapy for Muscle-Invasive Bladder Cancer. Peyrottes, A., Ouzaid, I., Califano, G., et al.[2021]

In a study of 39 patients with muscle-invasive bladder cancer, the combination of gemcitabine, cisplatin, and the immune checkpoint inhibitor pembrolizumab was effective, achieving pathologic downstaging in 56% of patients and complete pathologic response in 36%.

The treatment was generally safe, with common side effects including thrombocytopenia, anemia, and neutropenia, but no severe immune-related adverse events were reported, indicating a manageable safety profile for this neoadjuvant therapy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. Rose, TL., Harrison, MR., Deal, AM., et al.[2022]

Immune checkpoint inhibitors (ICIs) have shown promising efficacy and low toxicity in the neoadjuvant treatment of muscle invasive bladder cancer (MIBC), suggesting they could be a beneficial option compared to traditional chemotherapy.

However, results from large trials in the adjuvant setting have been conflicting, and there is a need for more long-term survival and toxicity data to fully understand the benefits of ICIs in clinical practice.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Role of Perioperative Immune Checkpoint Inhibitors in Muscle Invasive Bladder Cancer. Chhaya, S., Watts, I., Ng, K., et al.[2023]

Immunotherapy using immune checkpoint inhibitors has shown promise in treating muscle-invasive bladder cancer, both in neoadjuvant (before surgery) and adjuvant (after surgery) settings, with studies like PURE and ABACUS demonstrating their effectiveness in certain patient groups.

A Phase III study (CheckMate 247) indicated that adjuvant nivolumab therapy can be beneficial for high-risk urothelial cancer patients post-chemotherapy, achieving similar pathologic complete response rates as traditional cisplatin-based chemotherapy, suggesting a potential alternative for patients who cannot tolerate chemotherapy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Neoadjuvant or adjuvant immunotherapy in bladder cancer: biological opportunity or clinical utility? Petrelli, F., Perego, G., Vavassori, I., et al.[2022]

Cisplatin-based chemotherapy is currently the standard treatment for muscle-invasive bladder cancer, but recent studies suggest that immune checkpoint inhibitors may offer a promising alternative with better safety and efficacy, especially in patients with higher disease stages and specific biomarkers.

Pathological responses to immunotherapy have been particularly encouraging in patients with high PD-L1 expression and certain gene signatures, indicating that biomarker selection could enhance treatment outcomes in the future.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Neoadjuvant Immunotherapy: The Next Gold Standard Before Radical Surgery for Urothelial Cancer. Raggi, D., Moschini, M., Necchi, A.[2022]

Nivolumab plus ipilimumab showed durable and long-term efficacy in treating advanced non-small cell lung cancer (NSCLC) compared to chemotherapy, regardless of tumor PD-L1 expression levels.

These findings are based on updated results from part 1 of the phase 3 CheckMate 227 trial, indicating that this combination therapy could be a more effective frontline treatment option for NSCLC patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Nivolumab/Ipilimumab Combo Yields Durable Efficacy in Advanced NSCLC. Kahl, KL.[2021]

Nivolumab combined with ipilimumab significantly improves overall survival in adult patients with intermediate/poor-risk advanced renal cell carcinoma compared to sunitinib, with a hazard ratio of 0.63, indicating a 37% reduction in the risk of death.

In the study involving 1096 patients, the median overall survival was not reached for the nivolumab + ipilimumab group, while it was 25.95 months for the sunitinib group, highlighting the potential of this combination therapy for better long-term outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma. Ali, S., Camarero, J., Hennik, P., et al.[2021]

In a trial involving 24 patients with stage III urothelial cancer, 96% were able to undergo surgery within 12 weeks after receiving preoperative immunotherapy with ipilimumab and nivolumab, demonstrating the treatment's feasibility.

The combination therapy resulted in a 46% rate of pathological complete response (pCR) and 58% of patients had no remaining invasive disease, suggesting that this approach is effective regardless of the patients' baseline CD8+ T cell levels.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. van Dijk, N., Gil-Jimenez, A., Silina, K., et al.[2022]

Thirteen clinical trials are currently investigating the use of immune checkpoint inhibitors as a treatment for high-risk non-muscle-invasive bladder cancer, particularly in patients who have not responded to Bacillus Calmette-Guérin (BCG) therapy.

Preliminary results from trials like SWOG S1605 and Keynote-057 indicate that checkpoint inhibitors, such as Pembrolizumab, show promising antitumor activity and are generally well-tolerated, suggesting they could be a viable alternative for patients with BCG-unresponsive bladder cancer.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Immune checkpoints inhibitors in the management of high-risk non-muscle-invasive bladder cancer. A scoping review. García-Perdomo, HA., Sánchez, AL., Spiess, PE.[2022]

In a retrospective study of 31 patients with locally advanced or metastatic bladder cancer, the combination of tislelizumab and chemotherapy (TGC) showed a median progression-free survival (PFS) of 36 weeks, significantly better than the 29 weeks observed with chemotherapy alone (GC).

While TGC treatment resulted in a higher incidence of grade ≥3 treatment-related adverse events (35.7% vs 23.5% for GC), this increase was not statistically significant, indicating that TGC is generally well tolerated while providing promising antitumor activity.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Tislelizumab in combination with gemcitabine plus cisplatin chemotherapy as first-line adjuvant treatment for locally advanced or metastatic bladder cancer: a retrospective study. Ren, X., Tian, Y., Wang, Z., et al.[2022]

Citations

1.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC11082753/

Nivolumab + Ipilimumab as Immunotherapeutic Boost in ...

Results indicated that 21% of patients achieved partial or complete response (PR or CR) and had a median overall survival (OS) of 8.6 months (95% CI, 6.1-11.3 ...

2.

onclive.com

onclive.com/view/dr-sonpavde-on-os-data-with-ipilimumab-nivolumab-in-previously-untreated-advanced-urothelial-carcinoma

Dr Sonpavde on OS Data With Ipilimumab/Nivolumab in ...

In patients with tumor PD-L1 expression of at least 1%, the median OS was 17.2 months (95% CI, 12.3-23.2) and 15.2 (95% CI, 10.9-18.4) in the ...

3.

opdivo.com

opdivo.com/bladder-urinary-tract-cancer/clinical-trial-results/advanced-previously-treated-immunotherapy

Previously Treated Advanced Bladder or Urinary Tract ...

7 out of 270 people, or 3%, saw tumors disappear completely in response to OPDIVO® for previously treated advanced bladder cancer.

4.

sciencedirect.com

sciencedirect.com/science/article/pii/S0959804925005143

Final clinical analysis of pre-operative ipilimumab and ...

Our data demonstrate a 5-year PFS of 67% and OS of 70% after pre-operative ICB in stage III UC. Survival was not impaired for patients with ...

5.

cancernetwork.com

cancernetwork.com/view/nivolumab-ipilimumab-shows-improved-benefit-in-urothelial-carcinoma

Nivolumab/Ipilimumab Shows Improved Benefit in ...

In all cohorts, 62%, 77%, and 64% of patients had died. In first-line cohort 1, the median overall survival was 16.4 months (95% CI, 7.3-28.5); ...

6.

packageinserts.bms.com

packageinserts.bms.com/pi/pi_yervoy.pdf

YERVOY U.S. Prescribing Information

HIGHLIGHTS OF PRESCRIBING INFORMATION. These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing ...

7.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC8632774/

Adverse Effects and Toxicity of Immune Checkpoint ...

In the treatment of urothelial carcinoma, ICIs show obvious advantage and can enhance survival rates. However, their adverse effects are ...

8.

mayoclinic.org

mayoclinic.org/drugs-supplements/ipilimumab-intravenous-route/description/drg-20074841

Ipilimumab (intravenous route) - Side effects & uses

Ipilimumab injection is used in combination with nivolumab to treat melanoma (a type of skin cancer) that has spread or cannot be removed by surgery.

9.

jamanetwork.com

jamanetwork.com/journals/jamaoncology/fullarticle/2818570

Nivolumab + Ipilimumab as Immunotherapeutic Boost in ...

These findings suggest that second-/third-line nivolumab plus high-dose ipilimumab may benefit patients with metastatic urothelial carcinoma.

10.

ascopubs.org

ascopubs.org/doi/10.1200/JCO.2019.37.15_suppl.4518

Phase II study of nivolumab and ipilimumab for advanced ...

Nivolumab and ipilimumab has demonstrated safety and efficacy in urothelial carcinoma and other malignancies.